Annexin Pharmaceuticals
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion
Annexin Pharmaceuticals AB today announces that Redeye has published an interview with the company's CEO Anders Haegerstrand and CSO/CMO Anna Frostegård regarding the ongoing clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye diseases diabetic retinopathy (DR) and retinal vein occlusion (RVO) and a summary of the year. A webinar about RVO and the Annexin study conducted by Professor Paulo-Eduardo Stanga is also available.
Annexin has recently announced that the first two patients have been dosed in the ongoing Phase 2a study, which is being conducted at The Retina Clinic in London under the leadership of Professor Paulo-Eduardo Stanga. In the interview, Anders Haegerstrand and Anna Frostegård give an insight into why the study is important, inform about the chosen study design and the type of data that can be expected to show within DR and RVO, as well as how the company's partnership discussions are progressing.
The interview can be seen here: Redeye interview
Recently, Professor Paulo-Eduardo Stanga at The Retina Clinic held a webinar, Retinal Vein Occlusion: Clinical Features, Current Management, & Future Developments, where he describes RVO and reviews ANXV as a potential treatment for RVO and the ongoing phase 2a study. Information about Annexin's study begins at 15:30 minutes into the video.
The webinar can be viewed here: Retinal Vein Occlusion: Clinical Features, Current Management, & Future Developments
| Datum | 2025-12-18, kl 12:30 |
| Källa | MFN |